Koerber, S. A.
Kroener, R. C.
Dendl, K.
Kratochwil, C.
Fink, C. A.
Ristau, J.
Winter, E.
Herfarth, K.
Hatiboglu, G.
Hohenfellner, M.
Haberkorn, U.
Debus, J.
Giesel, F. L.
Funding for this research was provided by:
Universitätsklinikum Heidelberg
Article History
Received: 11 May 2022
Revised: 3 August 2022
Accepted: 4 August 2022
First Online: 23 August 2022
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (“S-433/2019”) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required. All patients, however, gave written consent to undergo the imaging procedures.
: Patent application for 18F-PSMA-1007 for UH and FLG. FLG is a medical advisory member for ABX Advanced Biochemical Compound, Sofie Biosciences and Telix Pharmaceuticals. JD and SAK received grants from View Ray Inc. SAK received honoraria from IBA Dosimetry outside the submitted work. JD received grants from CRI–The Clinical Research Institute GmbH, Accuray Incorporated, Accuray International Sàrl, RaySearch Laboratories AB, Vision RT limited, Astellas Pharma GmbH, Astra Zeneca GmbH, Solution Akademie GmbH, Ergomed PLC Surrey Research Park, Merck Serono GmbH, Siemens Healthcare GmbH, Quintiles GmbH, Pharmaceutical Research Associates GmbH, Boehringer Ingelheim Pharma GmbH Co, PTW-Freiburg Dr. Pychlau GmbH, Nanobiotix A. A., and IntraOP Medical outside the submitted work. All other authors have no relevant financial relationships to disclose.